Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
29 hedge funds and large institutions have $42.1M invested in Trillium Therapeutics Inc. in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
7% more funds holding
Funds holding: 27 → 29 (+2)
22% less capital invested
Capital invested by funds: $54M → $42.1M (-$11.9M)
78% less call options, than puts
Call options by funds: $4K | Put options by funds: $18K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$653K |
| 2 |
Renaissance Technologies
New York
|
+$652K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$649K |
| 4 |
Morgan Stanley
New York
|
+$375K |
| 5 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$233K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
-$2.91M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$2.09M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.61M |
| 4 |
Millennium Management
New York
|
-$18K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3.74K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | -$3.74K | -587 | -49% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $3K | -$1.04K | -163 | -25% |
|
|
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $379 | – | – | – |
|
|
NLVP
29
New Leaf Venture Partners
New York
| – | -$2.91M | -404,159 | Closed |
|
|
30
Victory Capital Management
San Antonio,
Texas
| – | -$2.09M | -290,571 | Closed |
|
31
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$453 | -71 | -82% |
|
TRIL Hedge Fund Activity: Q2 2018 in Review
29 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q2 2018, worth a combined $42.1M — down 22% from $54M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TRIL positions and 2 closed out — a net gain of 2 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $653K. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $2.91M sold.
- 29 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q2 2018, up from 27 in Q1 2018.
- Funds reported $42.1M of Trillium Therapeutics Inc. stock for Q2 2018, down 22% quarter-over-quarter.
- 4 funds opened new Trillium Therapeutics Inc. positions in Q2 2018 and 2 closed out, a net change of +2 holders.
- The largest Trillium Therapeutics Inc. buyer in Q2 2018 was Baker Bros. Advisors, an estimated $653K added.
- The largest Trillium Therapeutics Inc. seller in Q2 2018 was New Leaf Venture Partners, an estimated $2.91M sold.
Based on aggregated 13F filings for Q2 2018.